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Galectin-1  is  a  14.5-kDa  β-galactoside-binding 
protein  that  belongs  to  a  15-member  protein  family 
expressed by many different cell types. It exerts major 
roles  in  the  immune  system  [1,2]  and  is  involved  in 
the  progression  of  various  cancer  types  [3],  including 
melanomas  and  gliomas  [4].  Galectin-1  displays 
intracellular  (i.e.,  protein-protein  interactions)  and 
extracellular  (i.e.,  protein-oligosaccharide  interactions) 
functions  [5];  it  displays  marked  pro-angiogenic  [6] 
and  pro-migratory  effects  in  gliomas  and  melanomas 
and  confers  these  two  tumor  types  with  significant 
levels  of  resistance  to  chemotherapy  and  radiotherapy 
[4].  Galectin-1  also  aids  melanoma  [2]  and  glioma 
[4] cells in escaping attacks from the immune system, 
though great hopes have been placed in various types of 
immunotherapy (including vaccinotherapy) for combating 
melanomas and gliomas that are associated with dismal 
prognoses because of their marked intrinsic resistance to 
proapoptotic stimuli, such as conventional chemotherapy 
and radiotherapy [4]. 
With  respect  to  galectin-1-mediated  processes  of 
tumor  immune  escape,  it  has  been  demonstrated  that 
galectin-1  secreted  by  cancer  cells  kills  activated  T 
cells [1] and that targeted disruption of galectin-1 gene 
expression  results  in  enhanced  T  cell-mediated  tumor 
rejection [2]. In fact, galectin-1 selectively controls Th1- 
and Th17-mediated effector functions; it also induces the 
differentiation of tolerogenic dendritic cells through IL-
27- and IL-10-dependent pathways [7]. 
With respect to galectin-1-mediated pro-angiogenic 
effects, it has been shown that cancer cells present in 
hypoxic  areas  overexpress  galectin-1  [4]  and  that  this 
overexpression  leads  to  marked  pro-angiogenic  effects 
[6].  These  galectin-1-mediated  pro-angiogenic  effects 
are  controlled  by  the  ORP150  protein  in  the  cases  of 
glioma  [8]  and  melanoma  (unpublished  data).  Indeed, 
transiently  decreasing  galectin-1  expression  in  glioma 
cells  impairs  VEGF  maturation  (and  therefore  VEGF 
secretion from glioma cells) through marked decreases 
in ORP150 expression [8]. Thus, combining the standard 
surgery-radiotherapy-temozolomide  therapy  [4]  with 
anti-galectin-1 and anti-VEGF approaches could lead to 
significant therapeutic benefits when combating malignant 
gliomas  and  potentially  metastatic  melanomas  [4]. 
Moreover, by itself, galectin-1 promotes angiogenesis [6]. 
Cancer cells, but not endothelial cells, secrete galectin-1 
to  exert  their  hypoxia-mediated  pro-angiogenic  effects 
[9].  The  uptake  of  galectin-1  by  cultured  endothelial 
cells specifically promotes H-Ras signaling to the Raf/
mitogen-activated  protein  kinase/extracellular  signal-
regulated  kinase  (Erk)  kinase  (Mek)/Erk  cascade  and 
stimulates endothelial cell proliferation and migration [9].
Hypoxia  also  induces  increases  in  resistance  to 
conventional radiotherapy and chemotherapy. Transiently 
decreasing the expression of galectin-1 in experimental 
models of melanomas and gliomas significantly increases 
the therapeutic benefits contributed by the alkylating agent 
temozolomide, which induces sustained pro-autophagic 
effects followed by late apoptosis in melanoma and glioma 
cells [4]. Galectin-1-induced increases in chemotherapy 
resistance  involve  distinct  biochemical  pathways.  In 
melanoma cells, decreases in galectin-1 expression induce 
heat  shock  protein  70-mediated  lysosomal  membrane 
permeabilization, a process associated with the release of 
cathepsin B into the cytosol; this is believed to sensitize 
the cells to the pro-autophagic effects of temozolomide 
when grafted in vivo [4]. In glioma cells, galectin-1 has 
been found to modulate p53 transcriptional activity and to 
decrease p53-targeted gene expression, including DDIT3/
GADD153/  CHOP,  DUSP5 ATF3  and  GADD45A  [4]. 
The  decrease  in  galectin-1  expression  also  impairs 
the  expression  levels  of  other  genes  implicated  in 
chemoresistance, such as ORP150, HERP, GRP78/BiP, 
TRA1, BNIP3L, GADD45B and CYR61. 
Altogether, these findings clearly point to the fact that 
decreasing galectin-1 expression (e.g., using monoclonal 
antibodies  or  siRNAs  [8])  in  melanomas  and  gliomas 
may weaken the defenses of these two types of cancers 
against radiotherapy, chemotherapy and immunotherapy/
vaccine therapy; may reinforce antiangiogenic therapies; 
and may weaken both the invasive capacities of these 
cancers towards neighboring tissues (such as the brain 
parenchyma for gliomas) and (in the case of melanomas) 
their metastatic rates [4].
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